This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Spyros Papapetropoulos

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	3yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Spyros Papapetropoulos (50 yo)

less than a year

Mandato

Dr. Spyridon Papapetropoulos, M. D., Ph. D., also known as Spyros, serves as Director, President & Chief Executive Officer at Bionomics Limited from January 05, 2023. He serves as Member of Scientific Advi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Adrian Hinton	Financial Controller	less than a year	AU$323.78k	0.0048% A$ 700.6
Spyridon Papapetropoulos	CEO, President & Director	less than a year	Nessun dato	Nessun dato
Timothy Cunningham	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Paul Rolan	Consultant Chief Medical Officer of Clinical Neuroscience	no data	AU$102.00k	Nessun dato
Julie Kerner	Senior Vice President of Business Operations	less than a year	Nessun dato	Nessun dato
Atul Mahableshwarkar	Acting Chief Medical Officer	less than a year	Nessun dato	Nessun dato
Suzanne Irwin	Company Secretary	2.3yrs	Nessun dato	Nessun dato

0.3yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di BNO non è considerato esperto (durata media 0.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Spyridon Papapetropoulos	CEO, President & Director	less than a year	Nessun dato	Nessun dato
Errol B. De Souza	Non-Executive Director	15.5yrs	AU$4.03m	0.025% A$ 3.7k
David Wilson	Independent Non-Executive Director	7.2yrs	AU$87.00k	0.017% A$ 2.5k
Alan Fisher	Independent Non-Executive Chair of the Board	6.9yrs	AU$87.00k	0.0068% A$ 1.0k
Jane Ryan	Independent Non-Executive Director	2.8yrs	AU$93.15k	0% A$ 0
Srinivas Rao	Member of Clinical Advisory Board	1.8yrs	AU$57.75k	Nessun dato
Murray Stein	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Steven Williams	Scientific Advisor	no data	Nessun dato	Nessun dato
Allan Young	Scientific Advisor	no data	Nessun dato	Nessun dato
Marina Picciotto	Scientific Advisor	no data	Nessun dato	Nessun dato
Peter Miles Davies	Independent Non-Executive Director	2.1yrs	AU$77.00k	0.018% A$ 2.7k
Aaron N. Weaver	Independent Non-Executive Nominee Director	3.1yrs	AU$77.00k	Nessun dato

3.0yrs

Durata media

56.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di BNO non è considerato esperto (durata media del mandato 3 anni), il che suggerisce un nuovo consiglio.

This company listing is no longer active

Bionomics Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

High number of new directors

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.011 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

Revenue beats expectations

New 90-day high: AU$0.39

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

New 90-day high: AU$0.22

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - AU$0.0082 loss per share

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media